Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data

The treatment of hidradenitis suppurativa (HS) has always been a real challenge for dermatologists; to date, the only biologic drugs approved for HS are adalimumab, an anti-tumor necrosis factor (TNF)-α drug, authorized in 2015, and secukinumab, recently licensed. The management of this condition is...

Descripción completa

Detalles Bibliográficos
Autores principales: Martora, Fabrizio, Scalvenzi, Massimiliano, Battista, Teresa, Fornaro, Luigi, Potestio, Luca, Ruggiero, Angelo, Megna, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516125/
https://www.ncbi.nlm.nih.gov/pubmed/37745273
http://dx.doi.org/10.2147/CCID.S418748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516125/
https://www.ncbi.nlm.nih.gov/pubmed/37745273
http://dx.doi.org/10.2147/CCID.S418748

Ejemplares similares